Yuki Mukai1, Izumi Koike2, Tatsuya Matsunaga3, Naho Ruiz Yokota3, Syoko Takano2, Madoka Sugiura2, Mizuki Sato2, Etsuko Miyagi3, Masaharu Hata2. 1. Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan y_mukai@yokohama-cu.ac.jp. 2. Department of Radiation Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 3. Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Abstract
BACKGROUND/AIM: To investigate the role and outcomes of radiation therapy (RT) for stage IVB uterine cervical cancer (UCC) patients with lung (oligo) metastases due to the lack of recent reports on the subject. PATIENTS AND METHODS: The cohort for this retrospective study comprised 23 consecutive patients with UCC (squamous cell carcinoma, n=13) and lung metastases who had received pelvic RT. Ten had lung metastases only, including 7 with oligometastases (≤4 lung metastases); the remaining 13 also had other distant metastases. RESULTS: Nine (39.1%) of the 22 patients (95.7%) completed RT without interruption. The 1-year primary progression-free rate was 95.2%. The 1-year overall survival rate was 47.2 % (estimated median survival: 9 months). Significant prognostic factors for survival included: i) ≤4 lung metastases (p=0.035), ii) unilateral lung metastases (p=0.039), iii) primary tumor diameter <100 mm (p<0.001), and iv) ECOG performance status <1 (p=0.015). CONCLUSION: RT is safe and effective for stage IVB UCC patients with lung metastases. Copyright
BACKGROUND/AIM: To investigate the role and outcomes of radiation therapy (RT) for stage IVB uterine cervical cancer (UCC) patients with lung (oligo) metastases due to the lack of recent reports on the subject. PATIENTS AND METHODS: The cohort for this retrospective study comprised 23 consecutive patients with UCC (squamous cell carcinoma, n=13) and lung metastases who had received pelvic RT. Ten had lung metastases only, including 7 with oligometastases (≤4 lung metastases); the remaining 13 also had other distant metastases. RESULTS: Nine (39.1%) of the 22 patients (95.7%) completed RT without interruption. The 1-year primary progression-free rate was 95.2%. The 1-year overall survival rate was 47.2 % (estimated median survival: 9 months). Significant prognostic factors for survival included: i) ≤4 lung metastases (p=0.035), ii) unilateral lung metastases (p=0.039), iii) primary tumor diameter <100 mm (p<0.001), and iv) ECOG performance status <1 (p=0.015). CONCLUSION: RT is safe and effective for stage IVB UCC patients with lung metastases. Copyright
Authors: M A Quinn; J L Benedet; F Odicino; P Maisonneuve; U Beller; W T Creasman; A P M Heintz; H Y S Ngan; S Pecorelli Journal: Int J Gynaecol Obstet Date: 2006-11 Impact factor: 3.561
Authors: Matthew S Ning; Vamsi Ahobila; Anuja Jhingran; Shane R Stecklein; Michael Frumovitz; Kathleen M Schmeler; Patricia J Eifel; Ann H Klopp Journal: Gynecol Oncol Date: 2017-10-28 Impact factor: 5.482
Authors: Jose M Clavero; Claude Deschamps; Stephen D Cassivi; Mark S Allen; Francis C Nichols; Brigitte A Barrette; Dirk R Larson; Peter C Pairolero Journal: Ann Thorac Surg Date: 2006-06 Impact factor: 4.330
Authors: M Seki; K Nakagawa; S Tsuchiya; T Matsubara; I Kinoshita; S Y Weng; E Tsuchiya Journal: J Thorac Cardiovasc Surg Date: 1992-10 Impact factor: 5.209
Authors: G Panek; K Gawrychowski; P Sobiczewski; P Derlatka; A Danska-Bidzinska; L Gmyrek; M Bidzinski Journal: Int J Gynecol Cancer Date: 2007-04-26 Impact factor: 3.437